- Home
- XGN vs ZURA Comparison
XGN vs ZURA Comparison
Compare XGN & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XGN | ZURA |
|---|---|---|
| Founded | 2002 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.9M | 252.9M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | XGN | ZURA |
|---|---|---|
| Price | $7.01 | $4.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $13.67 | $11.38 |
| AVG Volume (30 Days) | 307.0K | ★ 359.5K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $63,599,000.00 | N/A |
| Revenue This Year | $22.15 | N/A |
| Revenue Next Year | $15.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.08 | N/A |
| 52 Week Low | $2.67 | $0.97 |
| 52 Week High | $12.23 | $4.68 |
Technical Indicators
Market Signals| Indicator | XGN | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 29.11 | 58.82 |
| Support Level | $7.01 | $3.58 |
| Resistance Level | $7.29 | $3.94 |
| Average True Range (ATR) | 0.32 | 0.25 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 15.42 | 82.96 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.